Abstract | OBJECTIVES: DESIGN: Retrospective analysis. SETTING: Single tertiary care university hospital. PARTICIPANTS: INTERVENTIONS: With IRB approval, the authors reviewed the charts of the identified patients and divided them into 2 groups based on whether they had received methylene blue. Two hundred twenty-six patients were identified who met the inclusion criteria for the study. Fifty-seven of these patients had received methylene blue for vasoplegia. The authors collected data on preoperative and intraoperative variables as well as outcomes. MEASUREMENTS AND MAIN RESULTS: The patients who received methylene blue had higher rates of in-hospital mortality, a compilation of morbidities, as well as renal failure and hyperbilirubinemia. A multiple logistic regression model demonstrated that receiving methylene blue was an independent predictor of in-hospital mortality (p value: 0.007, OR 4.26, 95% CI: 1.49-12.12), compilation of morbidities (p value: 0.001, OR 4.80, 95% CI: 1.85-12.43), and hyperbilirubinemia (p value:<0.001, OR 6.58, 95% CI: 2.91-14.89). Using propensity score matching, the association with morbidity was again seen but the association with mortality was not found. CONCLUSIONS: The current study identified the use of methylene blue as treatment for vasoplegia to be independently associated with poor outcomes. While further studies are required, a thorough risk-benefit analysis should be applied before using methylene blue and, perhaps, it should be relegated to rescue use and not as first-line therapy.
|
Authors | Menachem M Weiner, Hung-Mo Lin, Dennis Danforth, Srikar Rao, Leila Hosseinian, Gregory W Fischer |
Journal | Journal of cardiothoracic and vascular anesthesia
(J Cardiothorac Vasc Anesth)
Vol. 27
Issue 6
Pg. 1233-8
(Dec 2013)
ISSN: 1532-8422 [Electronic] United States |
PMID | 23972738
(Publication Type: Journal Article)
|
Copyright | Copyright © 2013 Elsevier Inc. All rights reserved. |
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antidotes
(adverse effects)
- Cardiac Surgical Procedures
- Cardiopulmonary Bypass
(adverse effects)
- Female
- Hospital Mortality
- Humans
- Logistic Models
- Male
- Methylene Blue
(adverse effects)
- Middle Aged
- Postoperative Complications
(epidemiology, mortality)
- Propensity Score
- Retrospective Studies
- Treatment Outcome
- Vasoplegia
(drug therapy, epidemiology, mortality)
- Young Adult
|